Phlebotomy and bolus subcutaneous deferoxamine in Algerian patients with thalassemia major or intermedia or sickle cell disease treated with hydroxyurea

被引：0
|
作者：
Bradai, Mohamed [1 ]
Bachir, Dora [2 ]
De Montalembert, Mariane [3 ]
机构：
[1] Hop Franz Fanon, Serv Hematol, Blida, Algeria
[2] Hop Henri Mondor, Ctr Drepanocytose, F-94010 Creteil, France
[3] Hop Necker Enfants Malad, Serv Pediat Gen, Paris, France
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3812
引用
收藏
页码：20B / 21B
页数：2
相关论文
共 50 条
  • [1] Side effects of hydroxyurea in patients with Thalassemia major and thalassemia intermedia and sickle cell anemia
    Ghasemi, A.
    Keikhaei, B.
    Ghodsi, R.
    IRANIAN JOURNAL OF PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2014, 4 (03) : 114 - 117
  • [2] Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia
    Bradai, Mohamed
    Pissard, Serge
    Abad, Mohand Tayeb
    Dechartres, Agnes
    Ribeil, Jean-Antoine
    Landais, Paul
    de Montalembert, Mariane
    TRANSFUSION, 2007, 47 (10) : 1830 - 1836
  • [3] PREVENTION OF CARDIAC DISEASE BY SUBCUTANEOUS DEFEROXAMINE IN PATIENTS WITH THALASSEMIA MAJOR
    WOLFE, L
    OLIVIERI, N
    SALLAN, D
    COLAN, S
    ROSE, V
    PROPPER, R
    FREEDMAN, MH
    NATHAN, DG
    NEW ENGLAND JOURNAL OF MEDICINE, 1985, 312 (25): : 1600 - 1603
  • [4] EFFECT OF HYDROXYUREA ON THALASSEMIA MAJOR AND THALASSEMIA INTERMEDIA IN IRANIAN PATIENTS
    Kosaryan, Mehrnoosh
    Vahidshahi, Koorosh
    Karami, Hosein
    Ehteshami, Sara
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2009, 25 (01) : 74 - 78
  • [5] CARDIAC DISEASE FREE SURVIVAL IN PATIENTS WITH THALASSEMIA MAJOR TREATED WITH SUBCUTANEOUS DEFEROXAMINE - AN UPDATE OF THE TORONTO COHORT
    OLIVIERI, NF
    MCGEE, A
    LIU, P
    KOREN, G
    FREEDMAN, MH
    BENSON, L
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1990, 612 : 585 - 586
  • [6] Human recombinant erythropoietin used alone and in combination with hydroxyurea in thalassemia intermedia and sickle cell disease patients.
    Politis, C
    Fragatou, S
    Vrettou, H
    Hatzilaou, J
    Tzioka, A
    Miariti, N
    Xanthaki, A
    Bassayiannis, A
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 1997, 42 (01): : 15 - 16
  • [7] The effect of hydroxyurea on the coagulation system in sickle cell anemia and β-thalassemia intermedia patients:: A preliminary study
    Koc, A
    Gumruk, F
    Gurgey, A
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2003, 20 (06) : 429 - 434
  • [8] Association of phlebotomy and subcutaneous bolus injection of deferoxamine for the treatment of anemic patients with iron overload
    Franchini, M
    Gandini, G
    Girelli, D
    Lippi, G
    de Gironcoli, M
    Aprili, G
    HAEMATOLOGICA, 2001, 86 (08) : 873 - 874
  • [9] Malignancies in sickle cell disease patients treated with hydroxyurea
    Ferster, A
    Sariban, E
    Meuleman, N
    BRITISH JOURNAL OF HAEMATOLOGY, 2003, 123 (02) : 368 - 369
  • [10] Long-term hydroxyurea therapy in thalassemia intermedia and thalassemia major patients.
    Alberto, FL
    Arruda, VR
    Lima, CSP
    Bordin, S
    Martins, J
    Saad, STO
    Costa, FF
    BLOOD, 1998, 92 (10) : 36B - 36B
12345